To hear about similar clinical trials, please enter your email below
Trial Title:
Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
NCT ID:
NCT05547737
Condition:
NSCLC
Conditions: Official terms:
Carcinoma, Non-Small-Cell Lung
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Drug
Intervention name:
Camrelizumab
Description:
Cross - line treatment of Camrelizumab in non-small cell lung cancer
Summary:
To explore the effectiveness and safety of Camrelizumab based cross-line therapy for
patients with advanced NSCLC in the real world
Criteria for eligibility:
Study pop:
Patients with stage IIIb, IV, or relapsed non-small cell lung cancer diagnosed
cytologically or histopathologically as EGFR/ALK-
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Signed informed consent and volunteered to join the study
2. Aged >=18 years
3. Patients with stage IIIb, IV, or relapsed non-small cell lung cancer diagnosed
cytologically or histopathologically as EGFR/ALK-
4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
5. At least one measurable lesion (according to RECIST 1.1)
6. No prior systemic therapy for advanced/metastatic NSCLC
7. contraception
Exclusion Criteria:
1. Those who are allergic to drug treatment；
2. Patients who were also treated with other immunodrugs or therapies；
3. Patients who are participating in other intervention studies；
4. Patients with other malignant tumors at the same time；
5. Pregnant or lactating women；
6. The investigator did not consider the patients eligible to participate in the study
under any other circumstances.
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Start date:
September 21, 2022
Completion date:
September 21, 2025
Lead sponsor:
Agency:
Henan Cancer Hospital
Agency class:
Other
Collaborator:
Agency:
Jiangsu HengRui Medicine Co., Ltd.
Agency class:
Industry
Source:
Henan Cancer Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05547737
